Slide 1: At the forefront of microbiome diagnostics & therapeutics
At the forefront of microbiome diagnostics & therapeutics Q3 FY25 Results ASX: MAP 30 APRIL 2025 Authorised for release by the Board of Directors
Slide 2: Disclaimer
Disclaimer 2 This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its a
Slide 3: Q3 FY25 Results: Financial Highlights
3 Q3 FY25 Results Financial Highlights
Slide 4: Q3 Financial Highlights
Q3 Financial Highlights 4 Continued Growth & Clinical Adoption of Testing Products in Australia and UK 3225 MetaXplore tests sold AU (+201% vs PCP) | 246 MetaXplore tests sold UK (+1,018% vs PCP) | 212 MetaPanel tests sold (+1,827% vs PCP) Continued Growth in Testing Volumes Australia 4,000 +240% •
Slide 5: Evolution of UK Test Sales across CY2025
Evolution of UK Test Sales across CY2025 5 Positive migration of customers and sales to MetaXplore 39% of the total GI tests sales in the UK already replaced by MetaXplore MetaXplore UK adoption • The migration of customers 160 45% over to MetaXplore is gathering MetaXplore Test Sales as % of Total
Slide 6: Evolution of Testing Product Revenue Mix
Evolution of Testing Product Revenue Mix 6 Executing sharp focus on key diagnostic testing products Research - Divested 100% Transferred to CMC in October 2024. Approx. $1m in revenue has been recognised from October 2024 to Feb 90% 2025. No further material revenue is forecast from March 2025 onwar
Slide 7: Q3 Financial Highlights
Q3 Financial Highlights 7 Forecasting strong close to FY25, despite Q3 impact from strategic change in revenue mix Annual Revenue Growth Quarterly Revenue & FY25 Q4 Guidance • Transitionary drop in Q3 revenue $18,000,000 +26% -34% $6,000,000 aligned to changes in product and Total Revenue -14% reven
Slide 8: Q3 FY25 Results: Business Highlights
8 SECTION 3 Q3 FY25 Results Business Highlights
Slide 9: Recent Milestones & Highlights
Recent Milestones & Highlights 9 DIAGNOSTICS THERAPEUTICS 1) Australia: Continued strong momentum in sales for Transitioned from research and development MetaXplore. heavy phase to capital lite, sales and - 3,225 tests sold, up 201% vs PCP partnering focused phase. - 698 ordering clinicians, up vs 1
Slide 10: Diagnostics Results
10 SUB-SECTION 3.1 DIAGNOSTICS RESULTS
Slide 11: Growing MetaXplore sales and clinical adoption in Australia
Growing MetaXplore sales 11 and clinical adoption in Australia MetaXplore Test Sales Volume (AU) MetaXplore All Time Ordering Clinicians (AU) • Q3 – 3,225 tests sold, up 201% vs PCP 4,392 • Q3 - 698 ordering clinicians, up 130% 1353 vs PCP 3,225 1045 • Q3 annualised run-rate of 12,900 2907 tests sol
Slide 12: Growing MetaPanel sales and clinical adoption in Australia
Growing MetaPanel sales and clinical 12 adoption in Australia MetaPanel Test Sales Volume (AU) • Q3 sales of 212, up 1,827% on PCP 407 • Landmark study results for IBD patients • 3 new key opinion leaders engaged 212 • Strategic agreement with major private Gastroenterology clinic to include MetaPan
Slide 13: Landmark MetaPanel Study Results
Landmark MetaPanel Study Results 13 Flare Study 1 • Two independent clinical studies Remission • MetaPanel test identifies gastrointestinal pathogens in >35% Study 2 of Inflammatory Bowel Disease (IBD) Severe patients experiencing flare flare • >60% of these pathogens are missed Positive MetaPanel b
Slide 14: Partnership with Major Gastroenterology Clinic
Partnership with Major Gastroenterology Clinic 14 • Microba partnered with Colonoscopy Clinic and Integrated Gut Health, one of Australia’s largest private gastroenterology services which sees more than 10,000 patients annually • The partnership aims to embed microbial diagnostic testing into routin
Slide 15: Growing MetaXplore sales and clinical adoption in UK
Growing MetaXplore sales 15 and clinical adoption in UK MetaXplore Test Sales Volume (UK) 160 • Q3 test sales for 246 140 137 • 98.6% MoM growth from Feb-Mar 120 • MetaXplore tests represent 39% of GI tests sold in the UK business as of 31 100 March 80 69 • Aligned to strategy, the whole UK 60 testi
Slide 16: Robust Supplement sales & revenue in United Kingdom
Robust Supplement sales & 16 revenue in United Kingdom Supplement Sales (UK) Supplement Revenue (UK) • Supplement revenues remain robust (+0.5% vs PCP) 35,000 $1,400,000 30,000 $1,200,000 • 30,029 supplements sold (-8.5% vs PCP) 25,000 $1,000,000 • Revenue increased vs PCP, supported by a 20,000 $80
Slide 17: Advancing into the US
Advancing into the US 17 • Entry strategy focused on 1 state, 1 metro area • USA represents >50% of global addressable market ($15bn of $25bn) $25B+ • Cash pay entry aligned to existing markets • Demonstrate performant clinician adoption and patient referral rates • Small sales and operational team
Slide 18: Therapeutics
18 SUB-SECTION 3.1 THERAPEUTICS
Slide 19: Transition to focus on partnering and revenue
19 Transition to focus on partnering and revenue • 5+ years of investment to develop a rich pipeline of live biotherapeutic assets leveraging Microba’s world leading databank • Deep preclinical and early clinical validation across key assets • Focus is now on partnering to deliver these assets to pa
Slide 20: Therapeutics Transition to sales & partnering focus
20 Therapeutics Transition to sales & partnering focus Commercial strategy Market value potential Assets Live Biotherapeutic Out license $1.5 - $11B Pharmaceutical drug (FDA – BLA) • Upfront MAP-315 • Strategic partnerships • Milestone payments • Royalties • Non-dilutive equity investment IBD Potent
Slide 21: Focus & Catalysts
21 SUB-SECTION 3.3 FOCUS & CATALYSTS
Slide 22: Key areas of focus & catalysts
Key areas of focus & catalysts 22 Diagnostics Financial Snapshot ASX Code MAP • Australia – continued momentum in diagnostic Market capitalisation1 $100m sales growth and clinical adoption Shares on issue 447.85m • United Kingdom – accelerating MetaXplore to full market access 52-week low / high1 $0
Slide 23: Microba Overview: Whole Business Recap
23 SECTION 4 Microba Overview Whole Business Recap
Slide 24: Company Snapshot
24 SUB-SECTION 4.1 COMPANY SNAPSHOT
Slide 25: >21,000 Research publications
Unequivocal evidence demonstrates that the human gut 25 microbiome is a critical component of disease >21,000 Research publications demonstrate a clear link between chronic diseases and the gut microbiome1 1 PubMed search terms "gut microbiome/microbiota" or "stool microbiome/microbiota" or "faecal
Slide 26: Changing the microbiome can change disease outcomes
Changing the microbiome can change disease outcomes 26 >150 Global clinical studies demonstrate that microbiome modulation can influence disease outcomes and clinical symptoms1 Infectious Disease Inflammatory Disease Autoimmune Disease Cancer Mental Health Metabolic Disorders Heart Disease Neurodege
Slide 27: Combating chronic disease through microbiome diagnostics and therapeutics
Combating chronic disease through microbiome 27 diagnostics and therapeutics $1.4 trillion healthcare disruption opportunity Microbiome testing to diagnose and match patients Microbiome therapy to treat with the right treatment chronic diseases $125B Est. TAM $1.3T Est. TAM Management estimate based
Slide 28: Sonic Healthcare partnership quote
28 “Our partnership with Microba exemplifies our commitment to invest in cutting edge developments in laboratory medicine. We see microbiome testing becoming a key part of pathology over coming years and are excited about the potential of this partnership and the opportunities that Microba's technol
Slide 29: Diagnostics
29 SUB-SECTION 4.2 DIAGNOSTICS
Slide 30: Our diagnostics vision
30 Our diagnostics vision: To combat disease through microbiome health
Slide 31: Our diagnostics focus
31 Our diagnostics focus Patients suffering from gastrointestinal disease Gastrointestinal Mental Cardiovascular Oncology Longevity Fertility →
Slide 32: Gastrointestinal Disease
Gastrointestinal Disease 32 Half of patients are not getting a resolution 37,310,000 47% Patients presenting annually in the US with lower GI abdominal symptoms* 21,500,000 53% Pain, bloating, other Resolved Unresolved 15,370,000 Diarrhoea 440,000 IBD % of patients achieving resolution of gastrointe
Slide 33: Addressing the GI symptom challenge
Addressing the GI symptom challenge 33 Microba’s comprehensive diagnostic products First line Gastrointestinal pathogen test Launched March 2024 Diagnosing pathogenic causes Stool DNA test. of GI symptoms 175 targets. Expertly curated clinical recommendations for targeted treatment. Second lin
Slide 34: 52% receiving critical new diagnoses and treatment
Getting answers for patients in need 34 Closing the gap on GI symptom diagnosis and treatment 100% 28% new insights with * 47% 50% ** Unresolved 24% new diagnoses with ** 0% % of patients achieving resolution of gastrointestinal symptoms after 5 years 52% receiving critical new diagnoses and treatme
Slide 35: A multi-billion dollar market opportunity
A multi-billion dollar market opportunity 35 $25B+ Total Market Size* * Assessment completed with Boston based MedTech specialist consultancy Veranex Inc. Assessment analysed US Medicare claims analysis for target patient populations, extrapolated Private and Medicaid numbers, populations and preval
Slide 36: Transforming standard of care
Transforming standard of care 36 A paradigm shift “After the first 4 months using the MetaPanel test, 24% of patients have been diagnosed with a pathogen that would have been undiagnosed or experienced delayed time to diagnosis and resolution. This is a breakthrough in infectious Dr Michael Wehrhahn
Slide 37: Changing lives every day
Changing lives every day 37 “Before completing the MetaXplore test with my practitioner, my health was in MetaXplore constant distress. I looked and felt bloated all the time, to the point of appearing six patient months pregnant. My severe constipation led to bowel movements only every 5-6 days wit
Slide 38: Changing lives every day
Changing lives every day 38 “I have struggled with gastrointestinal symptoms for over half my life. I have MetaXplore tried resolving with many specialists, restrictive eating plans and natural patient therapies. My MetaXplore test this year identified clear problems and a personalised treatment pla
Slide 39: Therapeutics
39 SUB-SECTION 4.3 THERAPEUTICS
Slide 40: Our Therapeutics Vision
40 Our Therapeutics Vision To combat disease through microbiome health 40
Slide 41: Our primary therapeutic focus
41 Our primary therapeutic focus Clinical: Patients suffering from Inflammatory Bowel Disease Gastrointestinal Autoimmune Oncology Allergy Neuro Cardiovascular → 41
Slide 42: Microba is Pioneering an Advanced AI/ML Approach
42 Microba is Pioneering an Advanced AI/ML Approach For the Development of Next Generation Precision Live Biotherapeutics Target Prediction Disease Relevant Activity Disease Donor Prevalence Isolation Human Data Driven Precision AI & Machine Microbiome Health Data Learning Therapeutics Biome Data In
Slide 43: Therapeutic pipeline & catalysts
43 Therapeutic pipeline & catalysts Development Core Program Discovery R&D Preclinical Phase 1 Phase 2 Partners MAP 315 Phase 2 IND submission currently (LBP) being compiled IBD (Ulcerative colitis) Undisclosed (LBP) Pre-clinical biology Undisclosed Immuno-oncology supporting lead (LBP) candidate se
Slide 44: Therapeutics Transition to sales & partnering focus
44 Therapeutics Transition to sales & partnering focus Commercial strategy Market value potential Assets Live Biotherapeutic Out license $1.5 - $11B Pharmaceutical drug (FDA – BLA) • Upfront MAP-315 • Strategic partnerships • Milestone payments • Royalties • Non-dilutive equity investment IBD Potent
Slide 45: Recent Pharma Transaction Comps
Recent Pharma Transaction Comps 45 Licensee / Licensor / Total Deal Date Deal Type Stage Upfront Acquiror Target Value July 2024 Acquisition Phase 2 - US$3.2B active June 2024 License Preclinical $150m US$1.7B October 2023 Acquisition Phase 2 - US$7.2B complete October 2023 License Phase 2b $500m US
Slide 46: Recent Next Gen Probiotic Activity
Recent Next Gen Probiotic Activity 46 Next generation Date Company Headline probiotic species Gut health pill aims to reduce fatigue and improve July 2024 FitBiomics Veillonella atypica endurance The Akkermansia Company launches dietary supplement June 2024 The Akkermansia Co Akkermansia muciniphila
Slide 47: Contacts
MICROBA “7 SUB-SECTION 4.4 CONTACTS
Slide 48: Contact
Dr Luke Reid CONTACT Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Laboratory Chairman Princess Alexandra Hospital pasquale.rombola@microba.com Woolloongabba QLD Australia